MRPL15 Antibody

What is MRPL15 and what is its biological significance?

MRPL15 is a mitochondrial ribosomal protein that plays a crucial role in protein synthesis within mitochondria. Research indicates that MRPL15 is significantly upregulated in multiple cancer types, particularly in Non-Small Cell Lung Cancer (NSCLC) . The protein participates in several critical cellular processes including metabolism-related pathways, DNA replication, and cell cycle signaling . Its expression appears to be linked to various clinical parameters including gender, clinical stage, lymph node status, and TP53 mutation status, making it an important target for cancer research . Understanding MRPL15's functions provides insights into mitochondrial biology and potentially reveals new therapeutic targets in cancer research.

What types of MRPL15 antibodies are commercially available for research?

Several types of MRPL15 antibodies are available for research applications. These primarily include:

• Rabbit polyclonal antibodies against human MRPL15, such as those manufactured by Atlas Antibodies

• Mouse monoclonal antibodies, which have been used in immunohistochemistry studies of lung cancer tissues

Each antibody type offers distinct advantages depending on the research application. Polyclonal antibodies generally provide higher sensitivity by recognizing multiple epitopes, while monoclonal antibodies offer greater specificity and batch-to-batch consistency. When selecting an antibody, researchers should consider the specific experimental requirements, including the detection method, sample type, and required sensitivity/specificity balance.

Which applications are MRPL15 antibodies validated for?

MRPL15 antibodies have been validated for several common laboratory techniques:

• Immunohistochemistry (IHC): Particularly useful for examining MRPL15 expression in tissue sections and tissue microarrays

• Immunocytochemistry/Immunofluorescence (ICC-IF): For cellular localization studies

• Western Blotting (WB): For protein expression analysis and quantification

Validation across these multiple platforms ensures researchers can confidently employ these antibodies in various experimental contexts. For example, in NSCLC studies, mouse monoclonal MRPL15 antibodies have been successfully utilized for immunohistochemical staining of tissue microarrays containing lung cancer tissues and adjacent normal tissues .

What are the recommended dilutions and concentrations for MRPL15 antibodies?

The optimal dilution varies by application and specific antibody formulation:

• For IHC applications: Mouse monoclonal MRPL15 antibodies have been successfully used at 1:300 dilution in lung cancer tissue studies

• For general applications: Commercial MRPL15 antibodies are typically supplied at concentrations around 0.1 mg/ml

Researchers should perform dilution series optimization for their specific experimental conditions, as factors such as tissue type, fixation method, and detection system can influence optimal antibody concentration. Pilot studies with a range of dilutions (e.g., 1:100 to 1:500) are recommended when first establishing protocols with a new antibody or sample type.

How does MRPL15 expression correlate with clinical outcomes in cancer research?

Multiple studies have established significant correlations between MRPL15 expression and clinical outcomes in cancer, particularly NSCLC:

These findings suggest that MRPL15 may serve as a potential prognostic biomarker in NSCLC and possibly other cancer types. Researchers investigating MRPL15 should consider incorporating survival analysis and clinicopathological correlations in their studies to further validate these associations.

What signaling pathways is MRPL15 involved in, and how can I study these interactions?

MRPL15 participates in several important signaling networks and biological pathways:

• Metabolism-related pathways: Including oxidative phosphorylation, carbon metabolism, and pyrimidine metabolism

• DNA replication pathways: KEGG pathway analysis has shown significant enrichment in DNA replication processes

• Cell cycle signaling: MRPL15 appears to influence cell cycle regulation through interaction with various kinases, miRNAs, and transcription factors

To study these interactions, researchers can employ:

• Co-immunoprecipitation assays to identify protein-protein interactions

• Pathway enrichment analysis using tools like KEGG on MRPL15 co-expressed genes

• Gene set enrichment analysis (GSEA) to identify biological processes associated with MRPL15 expression

• Protein-protein interaction (PPI) network analysis using platforms like GeneMANIA to examine interactions with kinases like HCK and transcription factors like ELK1

How can I analyze the relationship between MRPL15 expression and immune infiltration?

Research has revealed that MRPL15 expression is negatively correlated with immune infiltration in cancer microenvironments, including:

To analyze these relationships, researchers can:

• Perform immunohistochemical double staining for MRPL15 and immune cell markers

• Utilize computational tools to estimate immune cell fractions from bulk RNA-seq data

• Conduct correlation analyses between MRPL15 expression and established immune signature genes

• Investigate the impact of MRPL15 modulation on immune-related pathways through KEGG pathway analysis

This negative relationship suggests MRPL15 may influence tumor immune evasion, representing an important area for further investigation.

What are the recommended controls when using MRPL15 antibodies?

For robust MRPL15 antibody experiments, several controls should be incorporated:

• Positive controls: Use tissues or cell lines known to express MRPL15, such as NSCLC tissue samples which have been shown to overexpress MRPL15

• Negative controls: Include tissues with minimal MRPL15 expression or use adjacent normal lung tissues as comparison

• Technical controls:

  • Primary antibody omission control to assess non-specific binding of secondary antibodies

  • Isotype control antibodies to evaluate background staining

• Validation controls:

  • siRNA or CRISPR knockdown of MRPL15 to confirm antibody specificity

  • Blocking peptide competition assays when available

Implementing these controls ensures the reliability and specificity of MRPL15 detection across experimental applications.

What is the recommended protocol for immunohistochemical staining with MRPL15 antibodies?

For effective IHC staining with MRPL15 antibodies, researchers should follow this optimized protocol:

• Sample preparation:

  • Fix tissues in 10% neutral buffered formalin

  • Embed in paraffin and section at 4-5μm thickness

  • Mount on positively charged slides

• Antigen retrieval:

  • Heat-induced epitope retrieval in citrate buffer (pH 6.0) or EDTA buffer (pH 9.0)

  • Boil for 15-20 minutes followed by 20-minute cooling

• Staining procedure:

  • Block endogenous peroxidase with 3% H₂O₂

  • Apply protein block to reduce non-specific binding

  • Incubate with mouse monoclonal MRPL15 antibody at 1:300 dilution

  • Use appropriate detection system (e.g., HRP-polymer and DAB chromogen)

  • Counterstain with hematoxylin

• Scoring method:

  • Assess staining intensity: negative (0), weak (1), moderate (2), strong (3)

  • Evaluate percentage of positively stained area: 0-25% (1), 26-50% (2), 51-75% (3), >75% (4)

  • Calculate integrated score by multiplying intensity by percentage

  • Consider scores above 6 as high expression

This protocol has been successfully applied in studies of MRPL15 expression in lung cancer tissues .

How can I quantify MRPL15 expression in tissue microarrays?

Quantification of MRPL15 expression in tissue microarrays requires a systematic approach:

• Staining preparation:

  • Perform IHC staining as described in the protocol above

  • Include appropriate positive and negative controls

• Scoring methodology:

  • Use the integrated scoring system that combines staining intensity and percentage of positive cells

  • Employ at least two independent observers for scoring to ensure reliability

  • Consider automated image analysis software for objective quantification

• Data analysis:

  • Compare expression between tumor and adjacent normal tissues

  • Correlate expression levels with clinicopathological parameters

  • Apply appropriate statistical tests (e.g., t-test for differential expression, Chi-square for relationship with clinical features)

  • Utilize survival analysis methods like Kaplan-Meier and Cox regression to assess prognostic value

This comprehensive approach allows for reliable quantification and meaningful interpretation of MRPL15 expression patterns in tissue microarrays.

What techniques can be used to study MRPL15's role in metabolism-related pathways?

To investigate MRPL15's role in metabolism-related pathways, researchers can employ multiple complementary techniques:

• Gene expression analysis:

  • RNA-seq or microarray analysis to identify co-expressed genes

  • KEGG pathway analysis to determine enriched metabolic pathways

  • Gene Set Enrichment Analysis (GSEA) to identify associations with metabolic signatures

• Functional studies:

  • MRPL15 knockdown or overexpression followed by metabolic profiling

  • Seahorse XF analysis to measure mitochondrial respiration and glycolytic function

  • 13C-metabolite tracing to track metabolic flux through relevant pathways

• Protein interaction studies:

  • Co-immunoprecipitation followed by mass spectrometry to identify interacting partners

  • Proximity labeling techniques (BioID, APEX) to map the mitochondrial interactome

  • Protein-protein interaction network analysis using computational tools

• Clinical correlation studies:

  • Correlation of MRPL15 expression with expression of metabolism-related genes

  • Analysis of association between MRPL15 levels and metabolic characteristics of tumors

These approaches can provide comprehensive insights into how MRPL15 influences metabolic pathways, particularly in cancer contexts where metabolic reprogramming is a hallmark feature.

What are common challenges when using MRPL15 antibodies and how can they be addressed?

Researchers may encounter several challenges when working with MRPL15 antibodies:

• Background staining issues:

  • Cause: Insufficient blocking, antibody concentration too high, or non-specific binding

  • Solution: Optimize blocking conditions, titrate antibody dilutions, include appropriate controls

• Weak or absent staining:

  • Cause: Inadequate antigen retrieval, suboptimal antibody dilution, or protein degradation

  • Solution: Test different antigen retrieval methods, adjust antibody concentration, ensure proper sample handling

• Variability between experiments:

  • Cause: Inconsistent protocol execution or antibody lot variation

  • Solution: Standardize protocols, use the same antibody lot when possible, include internal controls

• Cross-reactivity concerns:

  • Cause: Antibody recognizing proteins with similar epitopes

  • Solution: Validate antibody specificity using MRPL15 knockdown controls, western blot verification before IHC

Addressing these challenges through methodical optimization will enhance the reliability and reproducibility of MRPL15 detection in research applications.

How can I optimize co-expression analysis to understand MRPL15's functional networks?

To optimize co-expression analysis for understanding MRPL15's functional networks:

• Data selection and preparation:

  • Utilize multiple independent datasets (like the 8 GEO series used in previous studies)

  • Apply appropriate normalization methods for cross-dataset comparability

  • Remove batch effects when combining datasets

• Co-expression analysis methods:

  • Perform Pearson correlation analysis to identify genes significantly associated with MRPL15

  • Apply weighted gene co-expression network analysis (WGCNA) to identify modules of co-expressed genes

  • Use tools like LinkedOmics to investigate co-expression patterns in different cancer types

• Network visualization and interpretation:

  • Visualize top correlated genes using heatmaps and network diagrams

  • Identify hub genes within the MRPL15-associated network

  • Perform pathway enrichment analysis on co-expressed gene clusters

• Functional validation:

  • Select key co-expressed genes (like LYPLA1, identified as strongly correlated with MRPL15)

  • Validate co-expression patterns using qPCR or western blotting

  • Perform co-depletion experiments to test functional relationships

This systematic approach has successfully revealed that MRPL15 participates in metabolism function, DNA replication, and cell cycle signaling while potentially inhibiting immune-related activities .

What are emerging areas of research regarding MRPL15 antibodies in cancer studies?

Several promising research directions are emerging for MRPL15 antibodies in cancer research:

• Therapeutic targeting potential:

  • Development of antibody-drug conjugates targeting MRPL15 in cancers with high expression

  • Investigation of MRPL15 as a biomarker for response to metabolism-targeting therapies

  • Exploration of combination therapies targeting MRPL15 and immune checkpoint inhibitors

• Precision medicine applications:

  • Stratification of patients based on MRPL15 expression for clinical trial enrollment

  • Development of companion diagnostics using MRPL15 antibodies

  • Investigation of MRPL15 expression as a predictor of therapy response

• Technical innovations:

  • Development of multiplex IHC panels including MRPL15 and immune markers

  • Creation of higher specificity recombinant antibodies against MRPL15

  • Application of spatial transcriptomics to correlate MRPL15 protein expression with local gene expression profiles

• Mechanistic studies:

  • Investigation of how MRPL15 negatively regulates immune infiltration

  • Exploration of MRPL15's role in metabolism reprogramming in cancer cells

  • Further characterization of MRPL15's interaction with transcription factors like ELK1

These emerging areas represent exciting opportunities for researchers to advance understanding of MRPL15's role in cancer biology and potential therapeutic applications.